Navigation Links
NuvaRing Blood-Clotting Claims Now Being Investigated by Resource4thePeople Attorneys
Date:3/23/2013

sed by her use of a NuvaRing IUD over seven years.
In her court filing, the woman said she has been forced to undergo a daily Coumadin regimen for her health problems, and suffers from depression and social anxiety.

Named as defendants are Organon Pharmaceuticals USA Inc., Organon International Inc. and Schering-Plough Corp., who, according to the court file, allegedly falsely marketed and sold the NuvaRing as a safe, efficient alternative to birth control pills.

As with the NuvaRing lawsuits in the multidistrict litigation, the Philadelphia woman claims that the defendants were negligent in not fully informing the public and health care professionals about increased risk of blood-clotting from the use of the contraceptive, according to the court filing.

The allegations cited in the multidistrict litigation claim that the NuvaRing, described by company officials as the first hormonal IUD, puts women at risk of suffering blood clots that can lead to life-threatening health problems because of the hormone mixture that prevents pregnancies.

The NuvaRing was approved by the Food and Drug Administration in 2001 after being created by Organon as a flexible IUD, or ring, hence the name. The IUD releases a low dose of etonogestrel and estrogen over three weeks, providing women the flexibility of a monthly contraceptive.

This flexibility was one of the marketing factors that made the NuvaRing what was described as an easy and healthy contraceptive choice to women who were not satisfied with the side effects caused by birth control pills and the necessity of taking them each day.

However, by 2011 the FDA released the findings of government research that put women who used the NuvaRing or other IUDs with a similar mixture of hormones at a 56 percent higher risk of suffering blood clotting that led to deep vein thrombosis and pulmonary embolisms than women on birth control pills.***

Resource4thePeople is committed t
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Federal NuvaRing Blood-Clotting Lawsuits Report: Resource4thePeople Updates Consumers with News That First Bellwether Trial Rescheduled to July
2. NuvaRing Lawsuit Filed on Behalf of a South Carolina Woman who Developed Two Blood Clots While Using NuvaRing, Reports Wright & Schulte LLC
3. NuvaRing Blood-Clotting Victims Still Eligible to File Lawsuits Through Resource4thePeople
4. DrugRisk Update: NuvaRing Lawsuit Trials to Begin This Year
5. DrugRisk Center Announces Court Postponement of NuvaRing Lawsuits
6. Law Firm Aggressively Litigating against Birth Control Makers for their Newer, but Allegedly Unsafer Products: Nuvaring, Yaz, BeYaz, Yasmin, Ocella, Gianvi
7. Yasmin Blood-Clotting Lawsuits Update: Resource4thePeople Providing Legal Assistance as Concerns Rise Over Health Risks
8. U-M sibling study discovers genetic region linked to control of key blood-clotting protein
9. Florida Social Security Disability Attorney Larry Disparti Says Sequester Cuts Make Filing Accurate, Complete Claims Crucial
10. New Business Letter Writing Book Claims To Be the Leading Resource For Writing Business Letters and Memos
11. Darvone-Darvocet Failure to Warn Claims Reinstated against Generic Drug Maker Wright & Schulte LLC Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... 23, 2014 Locks-Magnetic.com, a notable magnetic ... Moreover, all the new products are available at low ... manager is proud of the new emergency doors. The ... And customers can choose from several colors. All of ... quality emergency door release is not as easy as ...
(Date:11/23/2014)... November 23, 2014 SWAccessControl.com's high quality ... market. Recently, the company has announced its new collection ... offer on these high quality power suppliers. All the ... off. The special offer lasts until Dec. 20, 2014. ... of them have been supporting it for a long ...
(Date:11/23/2014)... Asher Milgrom, is a celebrity doctor ... was recently featured on International Business Times. ... of American Medical Aesthetics & Wellness, also known as ... scholarship to attend an M.D./Ph.D program at University of ... of Chicago, where his field of study was neuro-biochemistry. ...
(Date:11/23/2014)... November 23, 2014 Syngenta lawsuits are ... behalf of farmers and agribusinesses that have allegedly incurred ... commercialize Agrisure Viptera and Agrisure Duracade, genetically modified ... approved for sale in China. According to a report ... virtually ban U.S. corn imports. Because China is the ...
(Date:11/23/2014)... City, Utah (PRWEB) November 23, 2014 ... health insurance reimbursement for small businesses, announced their ... book, The End of Employer-Provided Health Insurance. ... insurance is the greatest financial risk facing most ... facing U.S. employers, small and large, when it ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 2Health News:Syngenta Lawsuits Being Investigated by Wright & Schulte LLC, Following China’s Rejection of Corn Shipments Tainted with Unapproved GMO Seed 3Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2
... active may help to tackle health threats, study says ... large body size, former professional football players aren,t at ... that looked at 201 retired NFL players. , The ... group of men from the population-based Dallas Heart Study ...
... -- The angiotensin system inhibitor irbesartan did not improve outcomes ... left ventricular ejection fraction. -- ... predominantly affects women and older patients; ... therapies is critical. NEW ORLEANS, Nov. 11 An angiotensin ...
... prevention trial on low-dose aspirin in diabetics,Japanese investigators report ... preventing the primary endpoints of all atherosclerotic events,although it ... - Low-dose aspirin was also associated with a reduced ... a subgroup of diabetics who,were over age 65., ...
... highlights:, -- Individually tailored doses of ... month as measured by platelet reactivity,monitoring by ... measures a,patient,s anti-platelet response to clopidogrel., ... bleeding events,between treatment and control groups., ...
... Study highlights:, - In a randomized, double-blind study ... C-reactive protein (hsCRP) greater than or equal to,2, those ... 31 heart attacks,and 33 strokes compared to 68 and ... analysis showed similar findings across gender, race,ethnicity and Framingham ...
... N.J., Nov. 11, 2008) The F.M. Kirby Foundation of ... Nursing at Rutgers, The State University of New Jersey, to ... Jersey residents. , The grant will also fund the work ... and service in the best academic tradition, said Interim Dean ...
Cached Medicine News:Health News:Retired NFL Players Don't Face Greater Heart Risk 2Health News:Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker 2Health News:Heart Failure Patients With Normal Left Ventricular Ejection Fraction Don't Benefit From Treatment With Angiotensin II Receptor Blocker 3Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 2Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 3Health News:Type 2 Diabetics Studied in Low-Dose Aspirin Trial 4Health News:Tailored Drug Delivery Reduces Adverse Effects After PCI 2Health News:Tailored Drug Delivery Reduces Adverse Effects After PCI 3Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 2Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 3Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 4Health News:Statin Reduces Heart Attack, Stroke Rates in Patients With Normal Cholesterol but Elevated C-Reactive Protein 5
(Date:11/21/2014)... , Nov. 21, 2014   Rock Creek ... that the Company is scheduled to present at the ... Francisco, CA on January 12-14, 2015. ... and CEO of Rock Creek Pharmaceuticals, will present preclinical ... cholinergic agonist which exhibits anti-inflammatory pharmacological characteristics. Dr. Mullan ...
(Date:11/21/2014)... November 2014 Clementia ... gegeben, dass die Europäische Arzneimittel-Agentur (European ... als Orphan-Medizinprodukt an Palovarotene vergeben hat, ... Behandlung von Fibrodysplasia ossificans progressiva (FOP). ... genetische Krankheit, die von schmerzhaften, wiederkehrenden ...
(Date:11/21/2014)... 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) announced ... will be presenting at the 26 th Annual Piper ... New York . The formal presentation is ... In addition, Mr. Krakauer and Jorgen B. Hansen , ... during the day. An audio webcast will ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 2Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 3Rock Creek Pharmaceuticals to Present at the Biotech Showcase 2015 4Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
... BioTrends Research Group, Inc. announces the release of the ... and Cimzia report. The survey was completed by ... qualitative interviews with a subset (n=20) of the survey respondents to ... employed to differentiate the products. Over the course of the ...
... , ATLANTA, Dec. 23 Alimera Sciences, Inc., a privately ... commercialization of prescription ophthalmic pharmaceuticals, today reported top-line results from ... The FAME Study consists of two Phase 3 pivotal clinical ... Iluvien in the treatment of diabetic macular edema (DME). The ...
Cached Medicine Technology:Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey 2Cimzia Draws Even With Simponi at Six Months Post Launch According to Recent BioTrends Survey 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 2Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 3Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 4Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 5Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema 6
EPO EIA Human Cytokines 021-SDX021 Erythropoietin Anemia...
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Medicine Products: